Ocuphire Pharma Inc
NASDAQ:OCUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ocuphire Pharma Inc
PP&E Net
Ocuphire Pharma Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocuphire Pharma Inc
NASDAQ:OCUP
|
PP&E Net
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
PP&E Net
$24.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
PP&E Net
$9.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
PP&E Net
$19.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
PP&E Net
$25.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
PP&E Net
$24.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
Ocuphire Pharma Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.
See Also
What is Ocuphire Pharma Inc's PP&E Net?
PP&E Net
0
USD
Based on the financial report for Jun 30, 2024, Ocuphire Pharma Inc's PP&E Net amounts to 0 USD.
